Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 132,200 shares, a decrease of 79.5% from the August 31st total of 644,600 shares. Based on an average daily volume of 9,810,000 shares, the short-interest ratio is presently 0.0 days. Currently, 6.1% of the shares of the stock are sold short. Currently, 6.1% of the shares of the stock are sold short. Based on an average daily volume of 9,810,000 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Franklin Resources Inc. acquired a new stake in Tharimmune, Inc. (NASDAQ:THAR) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 45,000 shares of the company’s stock, valued at approximately $88,000. Franklin Resources Inc. owned approximately 1.07% of Tharimmune as of its most recent SEC filing. 1.16% of the stock is currently owned by hedge funds and other institutional investors.

Tharimmune Trading Down 2.1%

THAR stock opened at $2.84 on Wednesday. The firm has a market cap of $16.76 million, a P/E ratio of -0.47 and a beta of 1.51. Tharimmune has a 1-year low of $0.95 and a 1-year high of $9.08. The business’s 50 day moving average is $2.89 and its 200-day moving average is $1.95.

Tharimmune (NASDAQ:THAR) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.06).

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).